Publikasi Scopus 2023 per tanggal 31 Januari 2023 (41 artikel)

Authors

Hasan I., Loho I.M., Setiawan P.B., Djumhana A., Purnomo H.D., Siregar L., Gani R.A., Sulaiman A.S., Lesmana C.R.A.

Author S Id

12776850800;57189584286;6507682592;6506054984;57070018900;57205384546;23495930300;57216938482;8977683000;

Title

Indonesian consensus on systemic therapies for hepatocellular carcinoma

Year

2023

Source Title

Asia-Pacific Journal of Clinical Oncology

Volume

Issue

Art No

Page Start

263

Page End

274

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130501126&doi=10.1111%2fajco.13768&partnerID=40&md5=4aebd9ca554567f4fe1979744ce3f123

Affiliations

Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Gastroentero-Hepatology, “Dharmais” National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Gastroentero-Hepatology, Department of Internal Medicine, Soetomo General Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Division of Gastroentero-Hepatology, Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia; Division of Gastroentero-Hepatology, Department of Internal Medicine, Kariadi General Hospital, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Authors With Affiliations

Hasan, I., Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Loho, I.M., Department of Gastroentero-Hepatology, “Dharmais” National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Setiawan, P.B., Division of Gastroentero-Hepatology, Department of Internal Medicine, Soetomo General Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Djumhana, A., Division of Gastroentero-Hepatology, Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia; Purnomo, H.D., Division of Gastroentero-Hepatology, Department of Internal Medicine, Kariadi General Hospital, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia; Siregar, L., Department of Gastroentero-Hepatology, “Dharmais” National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Gani, R.A., Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sulaiman, A.S., Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Abstract

Hepatocellular carcinoma (HCC) is a deadly cancer with a rising incidence in the last 20 years. Most patients are diagnosed late when curative treatment is no longer feasible. With the background of chronic liver disease in most patients, the management of HCC becomes more complicated, in which well-preserved liver function is a prerequisite for locoregional or systemic therapies. In 2008, sorafenib became the first systemic agent proven to provide survival benefit for patients with advanced-stage HCC. For nearly a decade, no treatment has succeeded in providing better results than sorafenib. However, numerous advances in systemic therapies have emerged in the last 5 years to fulfill the unmet needs of effective therapeutic options. Several agents have been approved for clinical use after positive results in phase III clinical trials, including lenvatinib, regorafenib, cabozantinib, ramucirumab, and lastly immune checkpoint inhibitor atezolizumab in combination with bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor. With various options available, knowledge on the clinical evidence of each drug, their safety profile, as well as the patient characteristics and preferences become mandatory in clinical decision making. The objective of this consensus is to help clinicians, health-care workers, and policy makers in providing best clinical care for HCC patients. © 2022 John Wiley & Sons Australia, Ltd.

Author Keywords

hepatocellular carcinoma; immune-checkpoint inhibitors; immunotherapy; systemic therapy; tyrosine-kinase inhibitors

Index Keywords

sorafenib; vasculotropin A; consensus; human; Indonesia; liver cell carcinoma; liver tumor; pathology; Carcinoma, Hepatocellular; Consensus; Humans; Indonesia; Liver Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A

Funding Details

Funding Text 1

The authors would like to thank Tiyas Hasnaa Faatinah, MD, for her assistance during translation process.

Funding Text 2

Funding Text 3

Publisher

John Wiley and Sons Inc

Issn

17437555

Isbn

Pubmed Id

35599455

Document Type

Article

Sjr Best Quartile

Sjr

453

Sjr Rank

10936